Company profile
UK company SC467513, incorporated on 15 January 2014.
Elasmogen - discovering and developing soloMERs
Elasmogen deliver effective therapeutics for improved treatment of auto-immune mediated, inflammatory diseases using soloMERs
Company number SC467513
Updated 07 Jul 2026 09:49
Financial period: 1 Feb 2024 to 31 Jan 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUyMzY3NTI3NGFkaXF6a2N4
Published 26 May 2026 12:39
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Biologics drug discovery company focussed on the site-specific delivery of soloMER domains (humanised VNARs) for the treatment of auto-inflammatory and oncology conditions.
Elasmogen develops biologic medication, specialising in the development soloMERs, that treat auto-immune inflammatory conditions.
Raised around £850 k to spin out in grant and equity finance in February 2016. Was second in the 2015 Converge Business Plan Challenge out of 200 technology companies that applied. First in the Life Sciences sector. Has established a number of collaborations with pharma partners. Was recognised as "Perfect Pitch" winners at BioTrinity 2016 and was shortlisted as new start spin-out of 2016 in the UK OBN awards. Was a finalist in the 2016 Innovate Showcase competition. CEO Dr Caroline Barelle was named one of the top 14 female CEO's in Europe and in 2018 and won the Risings Stars: Extraordinary Talent SE Life Sciences Scotland. Elasmogen has also won the Start-up Slam - "Most Innovative Company at BioFit 2018 and in the same year at the Entrepreneurial Scotland Summit Awards was made "Academic Entrepreneurial company of the Year" Raised additional equity and grants totally £1.2 M in February 2017. Raised an additional £1.6 M in grants, upfront and equity in 2018. Currently has term sheet for an additional £2 M expects to close March 2019. Has been used as a CASE study by BBSRC: http://www.bbsrc.ac.uk/news/impact/elasmogen-shark-proteins-for-drug-discovery/
1 Jun 2020 to 30 Nov 2020
no public description
1 Nov 2019 to 31 Jan 2022
To develop new targeted nanomedicines for the treatment of cancers with unmet clinical need using variable New Antigen Receptor technology.
1 Dec 2018 to 31 Mar 2022
To develop the knowledge and capability to design, construct and test new and efficacious bi-specific drugs for liver disease; a 'silent-epidemic' driven by growing levels of obesity and diabetes and where no effective drugs currently exists.
1 Aug 2018 to 31 Mar 2021
"Despite marked improvements in outcomes for cancer patients, 35% will succumb to the disease. First line chemotherapy treatments generally rely on the sensitivity of fast-growing cancers being more susceptible to toxic agents than ""normal"" healthy cells. The unpleasant side-effects of this treatment, together with a poor prognosis means there is an urg...
1 Feb 2017 to 31 Jan 2019
Elasmogen’s technology is a unique soloMER™ drug platform exploiting the power of proteins (biologics) as drugs but in small, simple and stable formats. Elasmogen have a pipeline of products in pre-clinical development for the treatment of inflammatory diseases of the eye. Current first-line therapies for these diseases are corticosteroids, but up to one ...
1 Apr 2016 to 28 Feb 2017
Even though there has been a marked improvement in the outcomes for cancer patients, 35% will still eventually succumb to the disease. Treatments still require clinicians to balance the administration of anti- cancer toxins with extreme patient side-effects. Therefore, there remains a significant need for more specific cancer therapies, providing opportun...
